Lamotrigine (All indications) updated on 04-22-2025

Early intrauterine deaths (< 22 weeks) / Spontaneous abortions

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16152
R67032		 Alsaadi (Lamotrigine) (Epilepsy) (Controls unexposed sick), 2020 Miscarriage 1st trimester retrospective cohort unexposed, sick Adjustment: No 1.50 [0.12;18.05] C 1/13   2/38 3 13
ref
S8913
R30123		 Miškov (Lamotrigine) (Controls unexposed, disease free), 2016 Spontaneous abortion during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No 26.64 [1.34;528.51] C
excluded (control group) 		3/37   0/128 3 37
ref
S8914
R30129		 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 Spontaneous abortion during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 0.73 [0.03;17.26] C 3/37   0/4 3 37
ref
Total 2 studies 1.14 [0.16;8.05] 6 50
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Alsaadi (Lamotrigine) (Epilepsy) (Controls unexposed sick), 2020Alsaadi, 2020 1 1.50[0.12; 18.05]31362%ROB confusion: criticalROB selection: unclearROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Miškov (Lamotrigine) (Controls unexposed, sick), 2016Miškov, 2016 2 0.73[0.03; 17.26]33738%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.14[0.16; 8.05]6500.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Epilepsy) (Controls unexposed sick; 2: Lamotrigine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.14[0.16; 8.05]6500%NAAlsaadi (Lamotrigine) (Epilepsy) (Controls unexposed sick), 2020 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.14[0.16; 8.05]6500%NAAlsaadi (Lamotrigine) (Epilepsy) (Controls unexposed sick), 2020 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 2 Tags Adjustment   - No  - No 1.14[0.16; 8.05]6500%NAAlsaadi (Lamotrigine) (Epilepsy) (Controls unexposed sick), 2020 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 2 All studiesAll studies 1.14[0.16; 8.05]6500%NAAlsaadi (Lamotrigine) (Epilepsy) (Controls unexposed sick), 2020 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8913

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale26.64[1.34; 528.51]337 -NAMiškov (Lamotrigine) (Controls unexposed, disease free), 2016 1 unexposed, sick controlsunexposed, sick controls 1.14[0.16; 8.05]6500%NAAlsaadi (Lamotrigine) (Epilepsy) (Controls unexposed sick), 2020 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 20.510.01.0